Quoretech’s Post

I am excited to highlight an article by my colleagues Brad Maruca and John Jaeger, recently published in SmartTRAK, titled "Market Access: What Medtech Can Learn from Pharma." Having worked with both Pharma and Medtech clients, I recognize the critical need for Medtech to adopt Pharma's robust clinical trials and reimbursement strategies. Too many innovative Medtech solutions struggle due to a lack of evidence and reimbursement support. Pharma excels by linking clinical outcomes to economic value and ensuring broad access through formularies. If Medtech took a similar approach, we could see many more innovations reaching their full potential in the market! #Medtech #Pharma #Innovation #MarketAccess #ClinicalTrials

#ROPCA joins the major European IHI AutoPiX project to revolutionize imaging in rheumatology 💡   We are proud to be part of the newly launched IHI AutoPiX project, a collaborative effort between European research partners, pharmaceutical companies, small and medium-sized enterprises (SMEs), and patient organizations under the Innovative Health Initiative (IHI) public-private partnership.   The AutoPiX project aims to improve the diagnosis, treatment decisions and monitoring of major rheumatic diseases, including rheumatoid arthritis (#RA), psoriatic arthritis, and axial spondyloarthritis, by leveraging AI to make clinical imaging more interpretable to scientists, clinicians, and patients.   This five-year project has a total budget of over €20 million, funded equally by the European Union and the EFPIA - European Federation of Pharmaceutical Industries and Associations, along with other industry partners. The initiative seeks to address critical unmet medical needs in rheumatology imaging, such as limited access to advanced techniques and gaps in precision for treatment selection. Coordinated by the Medical University of Vienna under the leadership of Prof. Dr. Daniel Aletaha and Assoc. Prof. Dr. Peter Mandl MD, PhD, and led by Robert Janiczek, PhD, from Johnson & Johnson, the project will unite efforts across Europe.   As part of the consortium, we at #ROPCA are committed to contributing to this innovative project, which has the potential to provide more precise diagnoses, personalized treatment paths, and reliable assessments of treatment responses. Johannes Schaeferhoff Søren Andreas Just Thiusius Rajeeth Savarimuthu Cora Meyer Laurence Despont Loreto Carmona Johannes Pleiner Melissa Hagendorn Alois Leidwein Vincent Bouget Isabel Morales Ivorra Natasha de Peyrecave Joeri Nicolaes Martin Brom Peter Gergely Robin Wamister Daniela Sieghart Xenofon Baraliakos Philipp Sewerin Gerhard Krönke PD Dr. med Arnd Kleyer Thomas Hügle Mikkel Østergaard    #IHI #AutoPiX #Rheumatology #ArtificialIntelligence #HealthTech #MedicalImaging #EFPIA #HealthcareInnovation #DigitalHealth #Biotech #AI #Pharmaceuticals #EuropeanUnion #MedicalResearch #ClinicalResearch

At mdgroup, we understand that a strong partnership between clinical trial sites and our mobile health teams is crucial for delivering exceptional patient care. Patients are at the heart of research, which is why we prioritize their needs above all else! #DecentralizedTrials #ClinicalResearch #MobileHealth

An article titled "Market Access: What Medtech Can Learn from Pharma" written by my colleague Brad Maruca published last week in SmartTRAK.   Medtech innovations often have the potential to revolutionize patient care. However, many of these promising technologies fall short of market adoption due to a lack of robust clinical evidence and strategic reimbursement plans. It’s disheartening to see such potential go unrealized because payers won’t cover the costs and hospitals can’t afford the financial risk.   However, biopharmaceutical manufacturer have set a roadmap. They invest in comprehensive clinical studies, link outcomes to health economic value, and ensure their treatments will be accessible through robust planning and market preparation. Medtech can and should adopt these proven strategies.   https://lnkd.in/e4fHcxTi   #Deloitte #Pharma #MarketAccess #Innovation #collaboration # Healthcare 

Radiopharmaceutical medical imaging company Cyclopharm has received its first purchase orders from two United States Veterans Health Administration (VA) Hospitals – part of the largest integrated US Government health care system in the United States (US). Cyclopharm CEO James McBrayer said: “The purchase orders received today for the Technegas Systems, combined with the national agreement awarded last month for the patient consumables, will allow for the first installations of Technegas within the VA system during the first few weeks of 2025." #manufacturing #australianmanufacturing #ASX #radiopharmaceuticals

Exciting news! Zai Lab and argenx secure NMPA approval for VYVGART Hytrulo, offering a breakthrough CIDP therapy in China, enhancing patient care and setting a new standard for global health collaborations. 🌟 #CIDP #HealthcareInnovation #RegulatoryAgencies #GlobalHealth #Pharma #ClinicalResearches #MarketAccessToday #MarketAccess

https://lnkd.in/dWGxW7rW - 𝐍𝐞𝐞𝐝𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $10.6 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2027  𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 6.7% Market is driven by factors such as Increasing preference for minimally invasive biopsies, and the rising vaccine demand globally. On the other hand, growing focus on the development of alternative drug delivery methods is expected to limit market growth to a certain extent in the coming years. 𝐆𝐞𝐫𝐦𝐚𝐧𝐲 𝐢𝐬 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭𝐞𝐝 𝐚𝐬 𝐭𝐡𝐞 𝐟𝐚𝐬𝐭𝐞𝐬𝐭 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐜𝐨𝐮𝐧𝐭𝐫𝐲 𝐨𝐟 𝐍𝐞𝐞𝐝𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 #𝐄𝐮𝐫𝐨𝐩𝐞. Based on the Europe region, the Needles Market is divided into Germany, UK, Italy, Spain, France, and RoE. Germany is forecasted to the fastest growing market of #Needles Market in Europe. The increasing incidence of neoplasm cases is the major factor driving the market for needles in the country. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 BD Hamilton Company Medtronic BKK B. Braun Melsungen AG Stryker Ethicon, Inc. Boston Scientific Unimed SA Terumo Medical Corporation Olympus Corporation Nipro Medical Corporation Argon Medical Devices, Inc. Merck KGaA, Darmstadt, Germany Merit Medical Systems, Inc. Greiner Holding AG ICU Medical UltiMed, Inc. Creganna Medical DTR Medical® Rocket Medical

Download the newest Healthcare Monthly Report from TM Capital. It covers the latest industry M&A deal activity and news, as well as trends in valuation. #TMCapital #ExtraordinaryOutcomes #ClientCare #Healthcare #BioTech #Pharma #LifeScience #Diagnostics #MedicalDevices #MergersandAcquisitions #InvestmentBank #FinancialAdvisor #Atlanta #NewYork #Boston

Cencora Announces Acquisition of Retina Consultants of America Exciting industry news this morning as Cencora, Inc. (NYSE: COR) enters into a definitive agreement to acquire Retina Consultants of America (RCA), in a move expected to enhance Cencora's leadership in specialty healthcare services. The acquisition, valued at approximately $4.6 billion, will add RCA’s nearly 300 retina specialists, operating across 23 states, to Cencora’s portfolio. RCA conducts over 2 million patient visits annually, making it a key player in the eyecare space. Cencora’s CEO, Robert Mauch, expressed excitement about leveraging the company’s strong operational infrastructure to support RCA in enhancing the provider experience, advancing innovative research, and improving patient outcomes. Meanwhile, David Brown, Co-Chair of RCA’s Medical Leadership Board, emphasized that joining forces with Cencora will further RCA’s mission to save sight and improve the lives of patients, enhancing its impact through innovation and a shared commitment to purpose-driven healthcare. This acquisition builds on Cencora's commitment to strengthening its Specialty division by helping providers manage practices while maintaining autonomy and patient-centric care. Additionally, Cencora aims to enhance RCA’s clinical research capabilities, including a network of 40 trial sites across Phases I-IV, positioning it as a key partner in advancing pharmaceutical innovation in the retina space. #HealthcareMergers #Ophthalmology #MSO #Innovation #Cencora #RetinaConsultants #Acquisition

🚀 Ocular Therapeutix Unveils AXPAXLI Trial Updates at the 43rd J.P. Morgan Healthcare Conference! 🌟 Join us as Ocular Therapeutix shares pivotal insights into the AXPAXLI trial, targeting wet age-related macular degeneration (wet AMD), at this prestigious event in San Francisco. 🔍 Key Highlights: - Dr. Pravin U. Dugel will discuss current enrollment and trial progress. - Preliminary findings and future opportunities for AXPAXLI will be explored. - Insights into corporate strategies, financial performance, and market expansion. With positive trends in enrollment, Ocular Therapeutix is poised to accelerate the approval timeline for AXPAXLI while diversifying its pipeline with innovative therapies like PAXTRAVA for glaucoma. 💡 This presentation is a must-watch for investors and stakeholders eager to understand Ocular Therapeutix's strategic direction in ocular health. 👉 Click on the link to access the live presentation! #ClinicalResearches #ClinicalTrials #General #HealthcareInnovation #JPMorganConference #OcularTherapeutix #Pharma #PharmaceuticalCompanies #RegulatoryAgencies #RetinalHealth #MarketAccess #MarketAccessToday